Vesugen

Longevity & Cellular

Also known as: Vesugen, KED peptide, Lys-Glu-Asp

Bioregulator PeptidesResearch phase: Limited human trialsRegulatory: Not FDA-approved; developed at the St. Petersburg Institute of Bioregulation and Gerontology; available as a research peptide and dietary supplement in some markets.

Mechanism

Vesugen is a three-amino-acid peptide bioregulator designed to support blood vessel health and cardiovascular function by activating genes involved in vascular repair and maintenance. It works by normalizing the function of endothelial cells that line your blood vessels, helping to maintain vessel elasticity, proper blood flow, and healthy blood pressure. As part of the Khavinson bioregulator series, it is used to address age-related vascular decline and support overall cardiovascular resilience.

Technical detail

Vesugen is a tripeptide (Lys-Glu-Asp) bioregulator that penetrates endothelial cell membranes and interacts with DNA regulatory sequences to modulate gene expression of endothelial nitric oxide synthase (eNOS), vascular endothelial growth factor (VEGF), and von Willebrand factor, restoring vascular homeostasis in aging endothelium. It downregulates endothelin-1 and intercellular adhesion molecule-1 (ICAM-1) expression, reducing vasoconstriction and leukocyte-mediated vascular inflammation that contribute to atherosclerotic plaque progression. Preclinical and limited clinical data demonstrate improvements in microcirculation parameters, reduction in arterial stiffness indices, and normalization of hemostatic balance through modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 ratios.

Effects

## Vesugen — System-by-System Effects ### Cardiovascular/Vascular System (Primary Target) - **Endothelial function**: Vesugen (Lys-Glu-Asp tripeptide) is a bioregulator targeting vascular endothelial tissue. Stimulates endothelial cell gene expression related to vascular repair, nitric oxide synthesis, and barrier integrity. [Tier 2 — Khavinson bioregulator research] - **Vascular tone regulation**: Supports proper vasodilation/vasoconstriction balance. May improve eNOS expression and nitric oxide bioavailability. [Tier 2] - **Microcirculation**: Improves capillary bed function and tissue perfusion. Particularly relevant for aging-related microvascular decline that affects every organ. [Tier 2-3] - **Atherosclerosis modulation**: May reduce endothelial inflammation and slow atherosclerotic progression. Anti-inflammatory effects at the vascular endothelium level. [Tier 2-3] ### Brain/Neurological (Via Cerebrovascular Perfusion) - **Cerebral blood flow**: Improved vascular function translates to better brain perfusion. Patients often report cognitive improvements attributed to enhanced cerebral blood flow. [Tier 3] - **Neurovascular coupling**: Supports the relationship between neuronal activity and local blood flow regulation. [Tier 3] ### Renal System - **Renal perfusion**: Kidney function depends heavily on microvascular health. Supporting vascular endothelial function may help maintain GFR in aging. [Tier 3 — extrapolated] ### Skin/Integumentary - **Dermal microcirculation**: Improved skin blood flow contributes to skin health, wound healing, and appearance. [Tier 3] ### Systemic Effects - **Blood pressure regulation**: Some patients report modest improvements in blood pressure, likely through improved endothelial function and NO bioavailability. [Tier 3] - **Anti-aging vascular support**: Vascular aging (arterial stiffness, endothelial dysfunction) is a central driver of age-related organ decline. Addressing vascular health impacts all downstream tissues. [Tier 2 for vascular aging biology]

Practitioner Guide

## Vesugen — Practitioner Guide ### Clinical Profile Vesugen is a synthetic tripeptide (Lys-Glu-Asp) bioregulator targeting vascular endothelial tissue. Part of the Khavinson cytogens class. ### Typical Protocols - **Standard course**: 1-2 capsules daily for 30 days, repeat 2-3 times per year - **Cardiovascular support**: 2 capsules daily for 30 days alongside cardiovascular risk factor management - **Bioregulator rotation**: Cycle vesugen with other vascular-supporting interventions ### Best Candidates - Patients with early atherosclerosis or endothelial dysfunction - Hypertensive patients as adjunct to standard therapy - Aging patients (50+) with declining vascular function - Patients with microcirculation issues (cold extremities, Raynaud-like symptoms) - Diabetic patients with microvascular complications (adjunct) ### Combination Strategies - **Vascular comprehensive**: Vesugen + Ventfort (complementary vascular bioregulators) + omega-3 + exercise - **Blood pressure support**: Vesugen + magnesium + CoQ10 + beet root/nitrate support - **Cognitive vascular**: Vesugen + pinealon + cerluten — supporting brain through vascular and neuronal pathways - **Anti-aging vascular**: Vesugen + NAD+ + GHK-Cu — vascular rejuvenation from multiple angles ### Clinical Observations - Benefits typically noticed over weeks to months (not acute) - Improved cold tolerance in extremities commonly reported - Some patients note improved exercise tolerance - Blood pressure improvements tend to be modest (5-10 mmHg systolic) - Very well tolerated with no significant adverse effects

Dosing Protocols

cardiovascular_supportbasic tier
Dose
10000mcg
Frequency
Once daily for 10-day cycles
Timing
Morning on an empty stomach, 20-30 minutes before food
Route
oral
Cycle
1-2 weeks

Vesugen targets vascular endothelium and cardiovascular tissue; morning dosing supports cardiovascular function during active hours; Khavinson 10-day cycling protocol

cardiovascular_supportbasic tier
Dose
10000mcg
Frequency
Once daily for 10-day cycles
Timing
Morning on an empty stomach
Route
subcutaneous
Cycle
1-2 weeks

Subcutaneous delivery of vascular bioregulator peptide; enhanced bioavailability for endothelial targeting; standard 10-day Khavinson protocol

Contraindications & Cautions

  • hard stop — Pregnancy
    No human safety data during pregnancy. Vascular bioregulator that modulates eNOS and VEGF gene expression poses theoretical risk to placental and fetal vascular development.
    Action: Do not use during pregnancy.
  • hard stop — Breastfeeding
    No data on excretion in breast milk. Safety not established during lactation.
    Action: Do not use while breastfeeding.
  • hard stop — Under 18 years of age
    Peptide protocols are not designed for pediatric use.
    Action: Do not provide to individuals under 18.
  • caution — General use
    Limited human safety data. Russian bioregulator peptide without large-scale clinical trials or international regulatory approval.
    Action: Use with awareness of limited evidence base. Monitor cardiovascular parameters.

Research Summary

## Vesugen — Research Summary ### Tier 1 - No Western RCTs available. ### Tier 2 - Published in vitro studies showing vesugen (KED peptide) modulates gene expression in vascular endothelial cell cultures. - Bioregulator research program data demonstrating improved endothelial function markers in animal models. - Khavinson laboratory publications on short peptide bioregulation of vascular tissue. ### Tier 3 - Clinical observations from European practitioners report improved vascular function, blood pressure, and peripheral circulation. - Practitioner experience supports use in aging populations for vascular maintenance. ### Key Research Gaps - No RCTs or placebo-controlled studies - No pharmacokinetic data for oral tripeptide bioavailability - No comparative studies with established vascular therapies

Build a personalized protocol with Vesugen →